Overview

Conversion Therapy With Sintilimab Plus CAPOX in Patients With Unresectable Locally Advanced or Limited Metastatic Adenocarcinoma of the Stomach or Esophagogastric Junction

Status:
Not yet recruiting

Trial end date:
2021-10-01

Target enrollment:

Participant gender:

Summary

This study aims to evaluate the efficacy and safety of Sintilimab plus CAPOX in the conversion therapy for patients with unresectable locally advanced or limited metastatic adenocarcinoma of the stomach or esophagogastric junction

Phase:

Phase 2

Details

Lead Sponsor:

Sichuan University

Treatments:

Capecitabine
Oxaliplatin